Torthaí cuardaigh - Jacob Valiyaveettil

  • 1 - 1 toradh as 1 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma

    ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma de réir Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L. Carstens, Jeremy B. Foote, Emily C. Graff, Yu-Hua Fang, Adam B. Keeton, Xi Chen, Jacob Valiyaveettil, Kristy Berry, Sejong Bae, Mehmet Akce, Greg Gorman, Karina J. Yoon, Upender Manne, M. R. Boyd, Donald J. Buchsbaum, Asfar S. Azmi, Yulia Y. Maxuitenko, Gary A. Piazza, Bassel F. El‐Rayes

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: